Sanofi Consumer Healthcare India Limited has informed the Exchange regarding Outcome of Board Meeting held on 2nd May 2025 to consider and approve the Unaudited Financial Results for the quarter ended 31st March 2025.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi Consumer Healthcare India reported its Q1 FY25 (quarter ended March 2025) results with revenue from operations at ₹1,726 million, down about 22% year-on-year from ₹2,216 million in the same quarter last year. Net profit fell to ₹500 million from ₹627 million, a decline of roughly 20%, translating to EPS of ₹21.69 versus ₹27.22. The fall is largely due to the ongoing impact of the voluntary product recall of Allegra Suspension, Combiflam Suspension and Depura products initiated in July 2024. The company has relaunched Depura Adult in this quarter and is working to bring back the remaining recalled products. For the full financial year ended December 2024, revenue stood at ₹7,245 million with a profit after tax of ₹1,810 million and EPS of ₹78.59. The statutory auditor, Kalyaniwalla & Mistry LLP, issued an unmodified limited review report with a clean conclusion. Separately, on April 30, 2025, parent group Sanofi closed the sale of a 50% controlling stake in Opella (its global consumer healthcare business) to CD&R, with Sanofi retaining a 48.2% stake.
The year-on-year decline reflects a temporary product recall shock rather than a structural weakness, and gradual relaunch of recalled products should support revenue recovery. The parent's global Opella transaction changes the ultimate ownership structure but Sanofi's continued significant stake should preserve continuity for the Indian listed entity. Investors should track the pace of product relaunches and the return of the recalled brands to shelves as the key near-term catalyst.